GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jenscare Scientific Co Ltd (HKSE:09877) » Definitions » ROE % Adjusted to Book Value

Jenscare Scientific Co (HKSE:09877) ROE % Adjusted to Book Value : -11.38% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jenscare Scientific Co ROE % Adjusted to Book Value?

Jenscare Scientific Co's ROE % for the quarter that ended in Jun. 2024 was -17.53%. Jenscare Scientific Co's PB Ratio for the quarter that ended in Jun. 2024 was 1.54. Jenscare Scientific Co's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -11.38%.


Jenscare Scientific Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Jenscare Scientific Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jenscare Scientific Co ROE % Adjusted to Book Value Chart

Jenscare Scientific Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - -1.75 -4.11

Jenscare Scientific Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial - -3.02 -2.86 -4.41 -11.38

Competitive Comparison of Jenscare Scientific Co's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Jenscare Scientific Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jenscare Scientific Co's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jenscare Scientific Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Jenscare Scientific Co's ROE % Adjusted to Book Value falls into.



Jenscare Scientific Co ROE % Adjusted to Book Value Calculation

Jenscare Scientific Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-28.22% / 6.87
=-4.11%

Jenscare Scientific Co's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-17.53% / 1.54
=-11.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jenscare Scientific Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Jenscare Scientific Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Jenscare Scientific Co Business Description

Traded in Other Exchanges
N/A
Address
No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN
Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure.
Executives
Li Hui 2501 Other
Trident Trust Company (hk) Limited 2301 Trustee
Trinity Elite I International Limited 2201 Interest of corporation controlled by you
Lv Shiwen 2501 Other
Ningbo Dixiang Venture Capital Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Shidi Industrial Development Co., Ltd. 2501 Other
Pan Fei 2201 Interest of corporation controlled by you
Shanghai Jiachen Investment Co.,ltd 2201 Interest of corporation controlled by you
Ningbo Sangdi Investment Management L.p. (limited Partnership) 2101 Beneficial owner
Ningbo Linfeng Biotechnology Co., Ltd. 2101 Beneficial owner
Hainan Yize Medical Technology Co., Limited 2201 Interest of corporation controlled by you
Hainan Maidi Enterprise Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Hualing Investment L.p. (limited Partnership) 2101 Beneficial owner
Hangzhou Chende Investment Partnership (limited Partnership) 2101 Beneficial owner
Ningbo Mukang Venture Capital Partnership (limited Partnership)

Jenscare Scientific Co Headlines

No Headlines